Editas Medicine EDIT
NASDAQ EDIT
$2.38 -0.13 (-4.99%)
At close: Nov 11, 2026 · 4:00 PM EST

Editas Medicine (EDIT) Return on Sales [ROS] (2015 - 2026)

Updated

Editas Medicine (EDIT) reported Return on Sales [ROS] of -325.44% for Q3 2025, up 107323.74 percentage points from -107649.18% a year earlier and up 1115.14 percentage points from the prior quarter.

Analysis

Editas Medicine (EDIT) Return on Sales [ROS] (2015 - 2026) Analysis & Trends

Over the twelve months ended Sep 30, 2025, Editas Medicine's Return on Sales [ROS] came in at -428.71%, down 58.68 percentage points year-over-year; for FY2024, it came in at -777.22%, down 560.67 percentage points from FY2023.

  • Return on Sales [ROS] has a five-year change of -90.84 percentage points (FY2019 to FY2024).
  • By year, Return on Sales [ROS] came in at -216.56% in FY2023 (+929.70 pp), -1146.26% in FY2022 (-390.13 pp), -756.13% in FY2021 (-607.52 pp) and -148.61% in FY2020 (+537.77 pp).
  • Five-year quarterly Return on Sales [ROS] spans a low of -136952.38% in Q3 2022 and a high of -39.90% in Q4 2023.
  • Year over year, Return on Sales [ROS] has now increased in each of the last three quarters, with an average year-over-year change of +50.26 percentage points over the last eight quarters.
  • The high point for year-over-year Return on Sales [ROS] in five years was Q3 2023 (a gain of 136012.29 percentage points); the low point was Q3 2022 (a drop of 136318.96 percentage points).
  • Per Business Quant data, the three quarters before Q3 2025 came in at -1440.58% (Q2 2025), -1635.10% (Q1 2025) and -152.24% (Q4 2024).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Editas Medicine 385.55 Mn -286.59 Mn 8.20 Mn -234.27%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -234.27%
Jun 30, 2026 -156.05%
Mar 31, 2026 -883.19%
Dec 31, 2025 -31.34%
Sep 30, 2025 -325.44%
Jun 30, 2025 -1,440.58%
Mar 31, 2025 -1,635.10%
Dec 31, 2024 -152.24%
Sep 30, 2024 -107,649.18%
Jun 30, 2024 -14,016.18%
Mar 31, 2024 -5,902.29%
Dec 31, 2023 -39.90%
Sep 30, 2023 -940.09%
Jun 30, 2023 -1,527.33%
Mar 31, 2023 -517.32%
Dec 31, 2022 -970.72%
Sep 30, 2022 -136,952.38%
Jun 30, 2022 -852.47%
Mar 31, 2022 -749.52%
Dec 31, 2021 -333.71%
API Access

Editas Medicine Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=EDIT&period=max&api_key=YOUR_API_KEY